Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Benitec Biopharma Inc. Common Stock

BNTC

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.

Last trade $8.11
Day change -$0.43 (-5.04%)
Day range $8.03 – $8.74
Volume 105,747
Market cap $308M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$308.46M
Price / earnings
—
Price / book
1.74×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.51×

Profitability

Earnings per share
-$1.26
Return on assets
-24.94%
Return on equity
-25.73%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
34×
Quick ratio
34×
Cash ratio
33.68×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.62M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BNTC, quarterly periods
Line itemQ4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024Q1 FY2025 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$6.54M$7.28M$7.54M$6.43M$6.97M$8.84M$5.42M$2.21M
Research and development$7.89M$6.3M$5.83M$3.37M$2.87M$6.5M$5.39M$3.59M
Total operating expenses$14.43M$13.58M$13.38M$9.8M$9.83M$15.34M$10.81M$5.79M
Operating income-$14.43M-$13.58M-$13.38M-$9.8M-$9.83M-$15.34M-$10.81M-$5.79M
Interest expense$1.57M$1.59M$0$0$1.04M$823K$0$0
Income before taxes-$12.81M-$11.94M-$11.84M-$8.97M-$8.81M-$14.5M-$9.55M-$5.06M
Income taxes$0$0$0$0$0$0$0$0
Net income-$12.81M-$11.94M-$11.84M-$8.97M-$8.81M-$14.5M-$9.55M-$5.06M
Net income attributable to common shareholders-$12.81M-$11.94M-$11.84M-$8.97M-$8.81M-$14.5M-$9.55M-$5.06M
EBITDA-$14.41M-$13.57M-$13.36M-$9.79M-$9.82M-$15.32M-$10.79M-$5.77M
Basic earnings per share-$0.26-$0.24-$0.26-$0.22-$0.21-$0.38-$0.26-$0.18
Diluted earnings per share-$0.26-$0.24-$0.26-$0.22-$0.21-$0.38-$0.26-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

Benitec Biopharma announced completion of 12-month follow-up for all six Cohort 1 patients in its BB-301 Phase 1b/2a trial for oculopharyngeal muscular dystrophy (OPMD)-related dysphagia, with clinically meaningful improvements observed. Cohort 2 is fully enrolled with three patients safely treated. The company held a Type C meeting with the FDA regarding pivotal study design and plans to initiate the pivotal trial in mid-2027. Benitec reported $180 million in cash as of June 30, 2026, with operating expenses of $51.2 million for fiscal year 2026.

GlobeNewswire Inc.

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Benitec Biopharma announced positive 24-month follow-up results from its BB-301 gene therapy clinical trial for oculopharyngeal muscular dystrophy (OPMD). Patient 1 demonstrated deepening improvements in swallowing function with 60% reduction in post-swallow residue and 78% improvement in dysphagic symptom burden at 24 months. All four patients who completed the 12-month follow-up period met responder criteria, showing durable response to the treatment.

GlobeNewswire Inc.

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference

Benitec Biopharma announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a clinical study in Oculopharyngeal Muscular Dystrophy (OPMD) patients. Interim clinical study updates for the first three subjects will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in March 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 26, 20231-for-17reverse split